ARTICLE | Deals
Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger
Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
June 6, 2022 9:36 PM UTC
After exploring strategic options, Yumanity has arrived at an outcome for its eight-year history of developing neuroscience therapies: a deal that will give its lead product and pipeline a home at J&J, and a reverse merger that will land Seattle-based Kineta on NASDAQ.
Launched in 2014 and co-founded by former Onyx Pharmaceuticals Inc. Chairman, President and CEO Tony Coles, Yumanity Therapeutics Inc. (NASDAQ:YMTX) has sought to address neurodegenerative disorders. Its sole clinical candidate is SCD1 inhibitor YTX-7739, in development for Parkinson’s disease...